AbCellera Biologics (ABCL) Asset Utilization Ratio (2021 - 2026)

AbCellera Biologics (ABCL) has 6 years of Asset Utilization Ratio data on file, last reported at 0.06 in Q1 2026.

• Quarterly Asset Utilization Ratio rose 247.9% year-over-year to 0.06 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 0.06 (up 247.9% YoY) and the FY2025 annual result came in at 0.06, up 173.14% from the prior year.
• Asset Utilization Ratio advanced to 0.06 in Q1 2026, from 0.06 in the prior quarter.
• In the past five years, Asset Utilization Ratio ranged from a high of 0.38 in Q3 2022 to a low of 0.02 in Q1 2025.
• A 5-year average of 0.11 and a median of 0.03 in 2023 frame the typical range for Asset Utilization Ratio.
• Annual changes were most pronounced in 2023 — Asset Utilization Ratio sank 91.92% — and 2026, when it surged 247.9%.
• Tracing ABCL's Asset Utilization Ratio over 5 years: stood at 0.31 in 2022, then slumped by 91.92% to 0.03 in 2023, then decreased by 17.37% to 0.02 in 2024, then surged by 164.43% to 0.06 in 2025, then advanced by 7.37% to 0.06 in 2026.
• The last three Asset Utilization Ratio figures came in at 0.06 (Q1 2026), 0.06 (Q4 2025), and 0.03 (Q3 2025), per Business Quant data.